Obi Umeh, MD, MSc, VP, Franchise Global Program Leader at Takeda, discusses interim results from a study investigating mezagitamab for the treatment of patients with IgA nephropathy. This…
Dana Rizk, MD, professor of medicine at the University of Alabama at Birmingham, discusses the approval of Fabhalta (iptacopan) for adults with IgA nephropathy. Iptacopan, a Factor B…
